Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

US clinical stage biopharma Candel Therapeutics (Nasdaq: CADL) has announced final survival data from a Phase IIa clinical ...

Candel Therapeutics (CADL) announced final survival data from a phase 2a clinical trial of CAN-2409 in patients with stage III/IV NSCLC, ...

Biotech Pharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announced its audited consolidated results for the year ended December 31, 2024 (the "Reporting Period").

Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2024 and highlighted recent business progress.

If a clinically meaningful PFS advantage is demonstrated in the absence of a decrement in OS, this could potentially support traditional approval.” The FDA further recommended Genelux request a ...

lived 19-20 months whether they received docetaxel plus pembrolizumab (Keytruda) or placebo. The addition of pembrolizumab did not improve overall survival (OS) in patients with PD-L1-positive ...

Why you can trust TechRadar We spend hours testing every product or service we review, so you can be sure you’re buying the best. Find out more about how we test. This review first appeared in ...

Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and often difficult conversations. Oncology nurses have a unique relationship ...

The median OS was 19.6 months with the combination and 19.0 months with docetaxel alone (HR, 0.92; 95% CI, 0.78-1.09; P =.17). The 12-month OS rate was 76.9% in the pembrolizumab arm and 73.2% in ...